Results 51 to 60 of about 24,471 (221)

A Non‐Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
A non‐canonical core transcriptional regulatory circuit, composed of ID3, SMAD3, and NR2F2, drives Osimertinib resistance in non‐small cell lung cancer through super‐enhancer‐mediated activation of EPAS1, which couples neuroendocrine differentiation with ferroptosis evasion.
Aochu Liu   +15 more
wiley   +1 more source

DeSeq2 output comparing the total RNA sequencing gene expression data of paired patient derived Ewing sarcoma and Ewing sarcoma CSCs.

open access: yes, 2021
List of differentially expressed genes comparing the total RNA sequencing data from paired patient derived Ewing sarcoma and Ewing sarcoma CSCs using ...
Burchill, Susan, Roundhill, Elizabeth
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma.

open access: yesPLoS ONE, 2013
The EWS/FLI translocation product is the causative oncogene in Ewing sarcoma and acts as an aberrant transcription factor. EWS/FLI dysregulates gene expression during tumorigenesis by abnormally activating or repressing genes.
Elizabeth T Wiles   +3 more
doaj   +1 more source

Bridged bicyclic carboxylic acids for treating osteosarcoma and Ewing sarcoma [PDF]

open access: yes, 2023
The present invention provides a composition for use in a method of treating osteosarcoma, Ewing sarcoma and/or a metastatic cancer originating from osteosarcoma or Ewing sarcoma. The present invention also provides a method of treating a cancer selected
Fraser, William, Green, Darrell
core  

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation.

open access: yesPLoS ONE, 2015
Metastatic Ewing Sarcoma carries a poor prognosis, and novel therapeutics to prevent and treat metastatic disease are greatly needed. Recent evidence demonstrates that tumor-associated macrophages in Ewing Sarcoma are associated with more advanced ...
Anthony J Hesketh   +8 more
doaj   +1 more source

Recent advances in targeted therapy for Ewing sarcoma [version 1; referees: 2 approved]

open access: yesF1000Research, 2016
Ewing sarcoma is an aggressive, poorly differentiated neoplasm of solid bone that disproportionally afflicts the young. Despite intensive multi-modal therapy and valiant efforts, 70% of patients with relapsed and metastatic Ewing sarcoma will succumb to ...
Kathleen I. Pishas, Stephen L. Lessnick
doaj   +1 more source

Primary Pulmonary Mesenchymal Neoplasm With EWSR1::CREM Fusion: Cytologic Findings and Molecular Diagnosis

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Background Primary pulmonary mesenchymal neoplasms with EWSR1::CREM fusion are rare. These lesions are challenging to diagnose by morphology and immunohistochemistry alone. Case A 66‐year‐old woman (ex‐smoker) was found to have a 1.3‐cm right lower lobe lung nodule that had grown very slowly over a 9‐year period.
Priya Upadhyay   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy